Urticaria – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of chronic urticaria (CU) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of CU for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the mature pharmaceutical markets of the United States, Europe, and Japan.
Clarivate Epidemiology’s CU forecast will answer the following questions:
- Of all people with CU, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with CU, how many in each developed country are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CU over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following CU patient populations:
- Diagnosed 12-month prevalent cases of CU.
- Total 12-month prevalent cases of spontaneous CU.
- Total 12-month prevalent cases of inducible CU.
- Total 12-month prevalent cases of spontaneous and inducible (overlap) CU.
- Diagnosed 12-month prevalent cases of spontaneous CU.
- Undiagnosed 12-month prevalent cases of spontaneous CU.
- Diagnosed 12-month prevalent cases of inducible CU.
- Undiagnosed 12-month prevalent cases of inducible CU.
- Diagnosed 12-month prevalent cases of spontaneous and inducible (overlap) CU.
- Undiagnosed 12-month prevalent cases of spontaneous and inducible (overlap) CU.
- Diagnosed drug-treated prevalent cases of spontaneous CU.
- Diagnosed non-drug-treated prevalent cases of spontaneous CU.
- Diagnosed drug-treated prevalent cases of inducible CU.
- Diagnosed non-drug-treated prevalent cases of inducible CU.
Note: Coverage may vary by country.
Table of contents
- Urticaria - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in / excluded from the analyses of chronic urticaria)
- Diagnosed 12-month prevalent cases of chronic urticaria
- Total 12-month prevalent cases of chronic spontaneous urticaria
- Total 12-month prevalent cases of chronic inducible urticaria
- Total 12-month prevalent cases of chronic spontaneous and inducible urticaria (overlap)
- Diagnosed 12-month prevalent cases of chronic spontaneous urticaria
- Diagnosed 12-month prevalent cases of chronic inducible urticaria
- Diagnosed 12-month prevalent cases of chronic spontaneous and inducible urticaria (overlap)
- Diagnosed drug-treated prevalent cases
- Risk / protective factors applied to disease forecast models
- Reference Materials
Saayali Khankari, B.D.S, M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Khankari worked as a clinical trial associate for a pharmaceutical company focusing on infectious disease and Phase III clinical trials. Ms. Khankari also worked as a research assistant analyzing qualitative data for multiple ongoing research studies at Boston Medical Center. She holds a master’s degree in public health with a major in epidemiology and biostatistics from Boston University and a bachelor’s degree in dental surgery.
Stephanie Niquita Phankon, M.B.B.S., M.P.H., Manager, Epidemiology. Ms. Phankon’s expertise is in autoimmune and inflammatory diseases and hematological malignancies. She holds a master’s in public health specializing in epidemiology from TISS in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China. She has been trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects.